[Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors.

Objective: To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.

Method: Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.

Results: Forty-one patients were included: 65% male, median age 54 years (SD=13).

Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors.

Objective: To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors.

Method: Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively.

Results: Forty-one patients were included: 65% male, median age 54 years (SD=13).

Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.

Objectives: to describe the efficacy and safety of the off-label use of alendronate in the treatment of osteoporosis in children and adolescents.

Method: a retrospective study (2008-2014) of all patients under 18 years who were dispensed alendronate for this indication. The criteria for initiating treatment were: bone mineral density with a Z-score ≤ -2.